Navigation Links
Dartmouth researchers develop new tool to identify genetic risk factors
Date:1/30/2014

(Lebanon, NH, 1/30/14) Dartmouth researchers developed a new biological pathway-based computational model, called the Pathway-based Human Phenotype Network (PHPN), to identify underlying genetic connections between different diseases as reported in BioDataMining this week. The PHPN mines the data present in large publicly available disease datasets to find shared SNPs, genes, or pathways and expresses them in a visual form.

"The PHPN offers a bird's eye view of the diseases and phenotype's relationships at the systems level," said Christian Darabos, PhD, post-doctoral fellow, Institute for Quantitative Biomedical Sciences (iQBS), Dartmouth College.

The PHPN uses information in human disease networks in conjunction with network science tools to show clusters of related disorders sharing common genetic backgrounds. It does so without the typical clinical classification of disease, in which all heart disease or all cancers are grouped together, based on clinical presentation. Dartmouth geneticists instead rely on the information contained in the PHPN's topology to automatically classify traits and diseases by their shared genetic mechanisms, such as common genes or pathways. PHPN explores the connections between the layers of the networks to find patterns and relationships.

"The intuitive network representation of the knowledge mined from several large-scale datasets makes the information accessible to anyone. It lies at the crossroads of computational genetics, systems biology, information theory, and network science," Darabos said.

PHPN supports the integration of genomic and phenotypic data to uncover significant links between traits, attributes, and disease. This offer tremendous potential in identifying risk factors for certain diseases. At the same time, it can reveal important targets for therapeutic intervention.

"As a proof of concept, the PHPN has proven capable of identifying well documented
'/>"/>

Contact: Donna Dubuc
Donna.M.Dubuc@Dartmouth.edu
603-653-3615
The Geisel School of Medicine at Dartmouth
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Dartmouth-led team gets $8 million grant to research arsenic in children
2. Dartmouth-led study shows diet alone can be significant source of arsenic
3. Dartmouth-led team discovers how plants avoid sunburn
4. Dartmouth researchers find there is no single sexy chin
5. Dartmouth researchers invent real time secondhand smoke sensor
6. Dartmouth neuroscientist finds free will has neural basis
7. Dartmouth research offers new control strategies for bipolar bark beetles
8. Mercury releases contaminate ocean fish: Dartmouth-led effort publishes major findings
9. Dartmouth research: The clocks are ticking and the climate is changing
10. Science stars head to Dartmouth for the E.E. Just Symposium
11. Dartmouth research imparts momentum to mobile health
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Dartmouth researchers develop new tool to identify genetic risk factors
(Date:7/30/2014)... ALBANY, New York , July 30, 2014 ... up-to-date research on Global Government Biometric Systems ... Analysis. The Global Biometric Systems Market ... global biometric systems market over the next ten ... industry, using detailed market size forecasts. ...
(Date:7/30/2014)... about what they eat, the Food and Drug Administration ... Nutrition Facts label found on nearly every food product ... Engineering News (C&EN), the weekly news magazine of ... and the fight that has ensued. , Britt Erickson, ... the Nutrition Facts label has remained largely the same ...
(Date:7/30/2014)... interest in neuroscience. A large number of genes ... Wallerian degeneration: transcription factor activation, immune response, myelin ... in the distal segment of the sciatic nerve ... gene expression between the proximal and distal segments ... Nantong University, China used microarrays to analyze changes ...
Breaking Biology News(10 mins):Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 3Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 4Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 5Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 6Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 7Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 8Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 9Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 10
... trauma, say from a sabertooth tiger attack, meant immediate death ... to survive severe injury caused by a car crash, gunshot ... does not know what to do when it survives an ... evolution. Nearly one third of the time, mechanisms in place ...
... that the ability of plants to defend themselves by accumulating ... some insects, and that such adaptation potentially echoes in the ... evolve to deal with high levels of the toxic element. ... and colleagues there and at the University of California, Berkeley, ...
... and proteins that explain how animals discern bitter from sweet, ... mutant fruit flies prefer eating sugar over sugar laced with ... that a single protein missing from the fly-equivalent of our ... the caffeine as if it were not there. , "No, ...
Cached Biology News:PNAS study reveals why organs fail following massive trauma 2PNAS study reveals why organs fail following massive trauma 3PNAS study reveals why organs fail following massive trauma 4PNAS study reveals why organs fail following massive trauma 5New moth variety disarms plants guarded by selenium 2Psst! Coffee drinkers: Fruit flies have something to tell you about caffeine 2Psst! Coffee drinkers: Fruit flies have something to tell you about caffeine 3
(Date:7/30/2014)... , July 30, 2014 Regulus ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended June ... U.S. financial markets close. Regulus will ... 6, 2014, at 5:00 pm Eastern Daylight Time to ...
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... today announced that the Companies intend to use a ... priority review voucher in connection with the Biologics License ... entitles the holder to designate a BLA for priority ... the filing date instead of the standard 10-month review. ...
(Date:7/30/2014)... 2014 W. R. Grace & ... the REVELERIS® Prep purification system , a ... and other researchers to perform both flash and ... , With the REVELERIS® Prep purification system, researchers ... modes with a simple touch of the screen, ...
(Date:7/30/2014)... 2014  Decision Resources Group finds that the ... the United States believe ... will be the level of savings achievable by ... lower cost to patients. Payers plan to leverage ... pricing expectations in order to encourage physician prescribing ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Grace Launches New REVELERIS® Prep Purification System 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... Group (USA), Inc. (the "Company" or "Tiens", NYSE AMEX: ... announced financial results for the third quarter and nine months ... of 2010 was $10.4 million, compared to $9.4 million for the ... 30, 2010 was $30.0 million, compared to $48.2 million for the ...
... 15, 2010 Celladon Corp., a biopharmaceutical company ... treatments for cardiovascular diseases, today announced that 12-month ... of MYDICAR® demonstrated significant improvements in clinical outcomes ... patients treated with the genetically-targeted enzyme replacement therapy. ...
... Webcast to Discuss ASSERT Clinical Trial Data ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
Cached Biology Technology:Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 2Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 3Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 4Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 5Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 6Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 7Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 8Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 9Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 2Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 3Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 4Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 2Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 3Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 4Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 5Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 6Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data 7
... The Corning CellBIND surface is produced ... a more hydrophilic surface giving more consistent, ... yields. CellBIND enhances cell attachment and growth ... serum-free medium. • CellBIND may provide a ...
... Bio-Plex suspension array system, 100-240 V, uses ... up to 100 proteins and peptides in ... composed of up to 100 color-coded bead ... with a unique reactant (enzyme substrates, receptors, ...
...
... the revolutionary Luminex 100 System delivers a ... real time enhancing your operational efficiency. This ... Luminex 100, the XY Platform, and the ... you to simultaneously assay up to 100 ...
Biology Products: